Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > In the spirit of anti-virals ... Pfizer acquisition
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Jun 28, 2022 11:17am
183 Views
Post# 34787572

RE:RE:RE:In the spirit of anti-virals ... Pfizer acquisition

RE:RE:RE:In the spirit of anti-virals ... Pfizer acquisition
Doccole wrote:

Let's hope mugs! 


i would love to see this move somewhere other than down.  



Assuming we'll get our turn as the market gets into it !!!

Did a cash burn review - with warrants and CITA payments included.
Everything hinges on a good P2 for acute and if we get that - cash is the least of our worries (IMO).
I'm assuming we grow the burn to $3M per month as well.
By the time cash is falling below $15M, we're considering NASDAQ anyway (option for some cash) - but - we also have cash from warrants coming through to fill the bank around that time.

Like I said, all hinges on a good P2 - then - likely will have momentum from other funnel work as well and we're deep into negotiations, if acute negotiations aren't already done.

Just one angle to consider if they stick to schedule.

---------------------------

Countdown to tomorrow foilks - all the best !!!


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities